Click here for slides on this topic


Dyslipidemia

An abnormal amount of lipids, including cholesterol and fat, in the blood. The characteristic dyslipidemia associated with insulin resistance and poorly controlled diabetes includes high levels of triglycerides, low levels of HDL-C, and partitioning of LDL-C into relatively small and dense particles.


The following content matched the glossary term: Dyslipidemia

Alirocumab Significantly Reduces LDL-C in High-Risk Patients in ODYSSEY FH I & FH II

Top

The PCSK9 inhibitor, alirocumab, significantly reduced LDL-C in high-risk patients with heterozygous FH in ODYSSEY FH I & FH II; from ESC 2015

NDEI.org Expert Commentary Silvio Inzucchi MD on IMPROVE-IT Subanalysis CV Benfits of Ezetimibe Exclusive to Subjects With Diabetes

Top

Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of IMPROVE-IT that showed the cardiovascular benefits of ezetimibe are restricted to patients with type 2 diabetes; from ESC Congress 2015.

CV Benefits of Ezetimibe Favor Patients With Type 2 Diabetes in IMPROVE-IT Analysis

Top

Data from a subanalysis of IMPROVE-IT at ESC Congress 2015 show that the cardiovascular benefits of ezetimibe are exclusive to individuals with type 2 diabetes. Includes expert commentary.

AACE 2015 guidelines Cardiovascular Disease Management

Top

Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

AACE 2015 guidelines Diabetes Diagnosis

Top

Summary of recommendations for screening and diagnosing type 2 diabetes from the 2015 AACE guidelines. 

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

ADA 2016 Children & Adolescents

Top

Recommendations for treating and managing diabetes in children from the 2016 ADA guidelines

ADA 2016 Cardiovascular Disease (CVD) and Diabetes

Top

Recommendations for CVD management, including lipids and BP, in patients with type 2 diabetes from the 2016 ADA diabetes guidelines

1 2 3 4 5 6 7 8 Next 

Slide Library Results

Search Results for: Dyslipidemia Slides Found: 106
Prevalence of the Insulin Resistance Syndrome (NCEP) in the US Population
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Effect of 4 Diets on Weight Loss and Cardiac Risk Factors
GLAI: Enrollment Criteria
Pioglitazone Reduces VLDL-TG Levels by Increasing LPL-Mediated Lipolysis
Non–HDL-C as a Predictor of Risk for CHD in Diabetes
INTERHEART: Waist-to-Hip Ratio Is a Better Predictor for MI Than BMI
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
LOADD: Nutritional Intervention for Persistent, Treated Hyperglycemia
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Considerations for Glycemia, BP, and Dyslipidemia
RYGB Surgery: Long-Term Health-Related Outcomes Design
RYGB Surgery: Incidence of Hypertension, Dyslipidemia Values at 6 Years
RYGB Surgery: Remission of Hypertension, Dyslipidemia Values at 6 Years
Comorbidities in Children and Adolescents With Type 2 Diabetes: Dyslipidemia (1 of 2)
Comorbidities in Children and Adolescents With Type 2 Diabetes: Dyslipidemia (2 of 2)
AIM-HIGH: Niacin + Statin Therapy for Cardiovascular Risk Reduction
AIM-HIGH: Design
Diabetes Surgery Study: Fewer Medications, Greater Weight Change with Gastric Bypass
SAVOR-TIMI 53: Design
LABS-2: 3-Yr Weight Loss After Bariatric Surgery
LABS-2: 3-Yr Mortality After Bariatric Surgery
LABS-2: 3-Yr Remission & Incidence of Cardiometabolic Outcomes After Bariatric Surgery
Teen-LABS: Rates of Complications 30 Days After Bariatric Surgery
AHA/ACC/TOS Obesity Guidelines: Predictors of Weight Loss With Bariatric Surgery
AHA/ACC/TOS Obesity Guidelines: Assessing BMI & Determining Readiness for Lifestyle Changes
AHA/ACC/TOS Obesity Guidelines: Treatment Algorithm for Overweight & Obese Adults Committed to Weight Loss
SEQUEL Subanalysis: Design
SAVOR TIMI 53 Pancreatitis Cancer Saxagliptin DPP-4 | NDEI
Diabetes Pregnancy Guidelines Preconception CVD Dyslipidemia | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission A1C Slide | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission Diabetes Medication | NDEI
Teen-LABS CVD Risk in Adolescents Undergoing Bariatric Surgery | NDEI
Safety Bariatric Surgery for BMI <35 at 1 Year
US Adults Who May Be Candidates for Obesity Therapy | NDEI
Phentermine + Topiramate A1C Targets Obese Subjects With Type 2 Diabetes | NDEI
Phentermine + Topiramate Decreases Need for Antidiabetic Treatments CONQUER | NDEI
Phentermine + Topiramate Safety Obesity Type 2 Diabetes | NDEI PPT
Treatment Strategies for Long-Term Weight Loss ENDO Obesity Guidelines | NDEI
AACE 2015 Guidelines Managing Dyslipidemia in Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Dyslipidemia Treatment PPT | NDEI
AACE 2015 Diabetes Guidelines Nephropathy Management Microvascular | NDEI
Cholesterol Targets LDL Type 2 Diabetes AHA ADA Guidelines | NDEI
Type 2 Diabetes and Prediabetes Screening for Children ADA Guidelines | NDEI
Diabetes Comorbities ADA Guidelines | NDEI PPT
Fatty Liver Disease Is A Diabetes Comorbidity ADA Guidelines | NDEI
Sleep Apnea Is A Diabetes Comorbidity ADA Guidelines | NDEI
Cancer Is A Diabetes Comorbidity ADA Guidelines | NDEI PPT
Fractures Are A Diabetes Comorbidity ADA Guidelines | NDEI
Low Testosterone Is A Comorbidity of Diabetes ADA Guidelines | NDEI
Hearing Impairment Is A Diabetes Comorbidity ADA Guidelines | NDEI
Cognitive Impairment & Diabetes ADA Guidelines Slide | NDEI
Lipid Management Recommendations ADA Diabetes Guidelines | NDEI
Statin Therapy in Type 2 Diabetes ADA Guidelines 2016 | NDEI PPT
Combination Statin Therapy in Type 2 Diabetes ADA Guidelines | NDEI PPT
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
Antiplatelet Therapy Recommendations ADA Guidelines | NDEI PPT
ADA Guidelines for Treating Dyslipidemia in Children With Type 1 Diabetes | NDEI
Lifestyle Recommendations from the NLA Cholesterol Guidelines | CCMD
Diets for Cholesterol Lowering NLA Cholesterol Guidelines | CCMD
Nutrition Recommendations NLA Cholesterol Guidelines | CCMD
Nutrition Recommendations to Treat High TG NLA Cholesterol Guidelines | CCMD
Lipid Screening in Children & Adolescents NLA Cholesterol Guidelines | CCMD
Lipoprotein Screening in Children & Adolescents NLA Cholesterol Guidelines | CCMD
Cascade Screening ifor FH in Children & Adolescents NLA Cholesterol Guidelines
Lifestyle Interventions for Children & Adolescents NLA Cholesterol Guidelines
Lipid Pharmacotherapy for Children & Adolescents NLA Cholesterol Guidelines
Treating Dyslipidemia in Women NLA Cholesterol Guidelines | CCMD
Pharmacologic Therapy for Dyslipidemia in Women NLA Cholesterol Guidelines
Managing Dyslipidemia During Pregnancy NLA Cholesterol Guidelines | CCMD
Managing Dyslipidemia in Women With PCOS NLA Cholesterol Guidelines
Managing Dyslipidemia in Women During Menopause NLA Cholesterol Guidelines
Primary & Secondary ASCVD Prevention in Older Adults NLA Cholesterol Guidelines
ASCVD Risk Assessment in Older Adults NLA Cholesterol Guidelines | CCMD
Pharmacotherapy for Dyslipidemia in Older Adults NLA Cholesterol Guidelines
Managing Dyslipidemia in Hispanics/Latinos NLA Cholesterol Guidelines | CCMD
Managing Dyslipidemia in African-Americans NLA Cholesterol Guidelines
Managing Dyslipidemia in Individuals With HIV NLA Cholesterol Guidelines
Managing Residual Risk After Lifestyle & Statin Therapy NLA Cholesterol Guidelines
PCSK9 Inhibitors for Residual CV Risk NLA Cholesterol Guidelines | CCMD
NLA Dyslipidemia Guidelines Summary CVD Slides | CCMD
NLA Cholesterol Guidelines LDL-C Treatment Targets | CCMD
NLA Cholesterol Guidelines Lipid Screening Recommendations PPT | CCMD
NLA Cholesterol Guidelines Lipid Treatment Goals | CCMD
NLA Guidelines Cholesterol & Triglyceride Targets CVD Slides | CCMD
NLA Guidelines Cholesterol Targets for Therapy CVD Slides | CCMD
NLA Guidelines Atherogenic Cholesterol Levels for Primary Prevention | CCMD
NLA Cholesterol Guidelines Lipid Treatment Goals | CCMD
NLA Guidelines CVD Risk Categories & Lipid Treatment | CCMD
NLA Cholesterol Guidelines Metabolic Syndrome Criteria | CCMD
NLA Cholesterol Guidelines ASCVD Risk Factors Slides | CCMD PPT
NLA Cholesterol Guidelines High or Very-High ASCVD Risk | CCMD
Very-High ASCVD Risk LDL Goals NLA Cholesterol Guidelines | CCMD
LDL-C Target for High ASCVD Risk NLA Cholesterol Guidelines | CCMD
NLA Cholesterol Guidelines Moderate ASCVD Risk PPT | CCMD
NLA Cholesterol Guidelines Low ASCVD Risk PPT | CCMD
ASCVD Risk Assessment Algorithm NLA Cholesterol Guidelines | CCMD
NLA Cholesterol Guidelines ASCVD Risk Refinement PPT | CCMD
NLA Cholesterol Guidelines Lifestyle Therapy ASCVD Risk PPT | CCMD
NLA Guidelines Patient-Centered Drug Therapy ASCVD Risk Reduction | CCMD
Cholesterol Treatment Algorithm to Reduce ASCVD NLA Guidelines | CCMD
Hypertriglyceridemia Management NLA Cholesterol Guidelines PPT | CCMD
Combination Lipid-Lowering Therapy NLA Cholesterol Guidelines PPT | CCMD
Severe Hypercholesterolemia Management FH NLA Cholesterol Guidelines | CCMD
FH Treatment & Management PCSK9 NLA Cholesterol Guidelines | CCMD
FH Treatment LDL-Apheresis NLA Cholesterol Guidelines PPT | CCMD